Friday, March 27th8.4°C
24931
24921

US drug maker AbbVie lifts its offer for British counterpart Shire to about $51.3 billion

NEW YORK, N.Y. - U.S. drugmaker AbbVie has boosted its offer for Shire by 11 per cent to about $51.3 billion, hoping it will be enough to pique the interest of its British counterpart.

Shire, known for its rare-disease drugs, has rejected three AbbVie offers to date.

North Chicago, Illinois-based AbbVie is now making an unsolicited offer of 51.15 British pounds ($87.57) per Shire PLC share in cash and stock. Its prior bid was worth about 46.26 pounds ($79.20) per share for a total value of 27 billion pounds ($46.2 billion).

AbbVie said that its revised proposal also increases the ownership held by Shire shareholders to about 24 per cent of the new holding company. It previously offered approximately 23 per cent ownership.

Shire said in a statement that it did not get a look at AbbVie's revised proposal before the company's announcement. Shire said its board will meet to consider the bid and that it will make a further announcement "in due course."

Last month AbbVie said that one of the reasons it was interested in Shire was that it saw a compelling tax break. AbbVie said at that time that it expected the combined company to pay a tax rate of about 13 per cent by 2016 after AbbVie reincorporates on the British island of Jersey, where Shire is headquartered. That would be down from its current rate of roughly 22 per cent.

Several other U.S. companies are using mergers to reincorporate in countries with lower tax rates. These moves are raising concerns among U.S. lawmakers since they can cost the federal government billions in tax revenue.

AbbVie executives have also said that the product portfolios of the two companies complement each other, and that the combination would immediately give Shire a broader geographic reach.

Shire has said that AbbVie's overtures undervalue the company and its prospects. The drugmaker has also said that its board had concerns about AbbVie's interest in making the move for tax purposes.

AbbVie, which was spun off from Abbott Laboratories last year, has until July 18 to either announce a firm offer or confirm that it won't make one under United Kingdom takeover laws.

AbbVie's stock fell $1.18, or 2.1 per cent, to $56.22 in Tuesday morning trading.

The Canadian Press


Read more Business News

25603


Recent Trending




Today's Market
S&P TSX14805.44-64.36
S&P CDNX678.97-0.59
DJIA17686.50+8.27
Nasdaq4878.83+15.47
S&P 5002058.51+2.36
CDN Dollar0.7952-0.0058
Gold1196.30-8.80
Oil50.08-1.35
Lumber281.50-4.50
Natural Gas2.609-0.063

 
Okanagan Companies
Pacific Safety0.125-0.005
Knighthawk0.010.00
QHR Technologies Inc1.49-0.01
Cantex0.03-0.01
Anavex Life Sciences0.22+0.01
Metalex Ventures0.04-0.01
Russel Metals24.64-0.04
Copper Mountain Mining1.11-0.02
Colorado Resources0.11-0.01
ReliaBrand Inc0.006-0.001
Sunrise Resources Ltd0.045+0.000
Mission Ready Services0.27+0.04
Decisive Dividend Corporation2.10+0.32

 





FEATURED Property
2161628330 Prestwick Lane
$679,000
more details
image2image2image2
Click here to feature your property
Please wait... loading


CRA Notice of Assessment

Many Canadians rush to file their taxes on time each year and don’t think about it until the next year. One of the most overlooked notices received from the CRA annually is the annual Notice of ...


Medical confidential?

If ICBC asks your doctor for your information you may wonder: Can ICBC ask my doctor for my medical information? Can ICBC request a medical report from my doctor without my consent? What is ICBC entit...


Stay out of sales limbo!

Have you ever had a series of good meetings with a prospect … gathered all kinds of information … and given what you thought was a great presentation … only to receive a response ...

_



25666




Member of BC Press Council